Business Description
Staidson (Beijing) Biopharmaceuticals Co Ltd
NAICS : 325412
SIC : 2834
ISIN : CNE100001237
Description
Financial Strength
8/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Cash-To-Debt | 362.14 | |||||
Equity-to-Asset | 0.8 | |||||
Piotroski F-Score | 2/9 | |||||
Altman Z-Score | 7.18 | |||||
Beneish M-Score | -3.27 | |||||
WACC vs ROIC |
Growth Rank
1/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | -5 | |||||
3-Year EBITDA Growth Rate | -38.8 | |||||
3-Year EPS without NRI Growth Rate | -40 | |||||
3-Year FCF Growth Rate | -16.9 | |||||
3-Year Book Growth Rate | -13.8 |
Momentum Rank
5/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
5-Day RSI | 32.11 | |||||
9-Day RSI | 33.46 | |||||
14-Day RSI | 35.82 | |||||
3-1 Month Momentum % | 3.96 | |||||
6-1 Month Momentum % | 36.4 | |||||
12-1 Month Momentum % | -15.01 |
Liquidity Ratio
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Current Ratio | 1.1 | |||||
Quick Ratio | 0.98 | |||||
Cash Ratio | 0.25 | |||||
Days Inventory | 130.63 | |||||
Days Sales Outstanding | 58.42 | |||||
Days Payable | 406.89 |
Dividend & Buy Back
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -0.1 | |||||
Shareholder Yield % | 0.25 |
Profitability Rank
3/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Gross Margin % | 82.3 | |||||
Operating Margin % | -51.76 | |||||
Net Margin % | -63.67 | |||||
FCF Margin % | -38.86 | |||||
ROE % | -21.03 | |||||
ROA % | -16.62 | |||||
ROIC % | -17.96 | |||||
3-Year ROIIC % | 983.62 | |||||
ROC (Joel Greenblatt) % | -74.24 | |||||
ROCE % | -16.71 | |||||
Years of Profitability over Past 10-Year | 6 |
GF Value Rank
8/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Shiller PE Ratio | 168.75 | |||||
PS Ratio | 7.56 | |||||
PB Ratio | 3.13 | |||||
Price-to-Tangible-Book | 3.65 | |||||
EV-to-EBIT | -16.89 | |||||
EV-to-EBITDA | -16.89 | |||||
EV-to-Revenue | 9.22 | |||||
EV-to-FCF | -23.32 | |||||
Price-to-GF-Value | 0.77 | |||||
Price-to-Median-PS-Value | 0.89 | |||||
Earnings Yield (Greenblatt) % | -5.92 | |||||
FCF Yield % | -4.23 | |||||
Forward Rate of Return (Yacktman) % | -18.64 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Annualized Return % Â
Total Annual Return % Â
Staidson (Beijing) Biopharmaceuticals Co Ltd Executives
DetailsAnalyst Estimate
Key Statistics
Name | Value | ||
---|---|---|---|
Revenue (TTM) (Mil ¥) | 350.711 | ||
EPS (TTM) (Â¥) | -0.472 | ||
Beta | 1.43 | ||
3-Year Sharpe Ratio | -0.44 | ||
3-Year Sortino Ratio | -0.62 | ||
Volatility % | 42.27 | ||
14-Day RSI | 35.82 | ||
14-Day ATR (Â¥) | 0.322353 | ||
20-Day SMA (Â¥) | 7.276 | ||
12-1 Month Momentum % | -15.01 | ||
52-Week Range (Â¥) | 5.41 - 9.4 | ||
Shares Outstanding (Mil) | 477.77 |
Piotroski F-Score Details
Component | Result | ||
---|---|---|---|
Piotroski F-Score | 2 | ||
Positive ROA | |||
Positive CFROA | |||
Higher ROA yoy | |||
CFROA > ROA | |||
Lower Leverage yoy | |||
Higher Current Ratio yoy | |||
Less Shares Outstanding yoy | |||
Higher Gross Margin yoy | |||
Higher Asset Turnover yoy |
Staidson (Beijing) Biopharmaceuticals Co Ltd Filings
Filing Date | Document Date | Form | ||
---|---|---|---|---|
No Filing Data |
Staidson (Beijing) Biopharmaceuticals Co Ltd Stock Events
Event | Date | Price (Â¥) | ||
---|---|---|---|---|
No Event Data |
Staidson (Beijing) Biopharmaceuticals Co Ltd Frequently Asked Questions
What is Staidson (Beijing) Biopharmaceuticals Co Ltd(SZSE:300204)'s stock price today?
When is next earnings date of Staidson (Beijing) Biopharmaceuticals Co Ltd(SZSE:300204)?
Does Staidson (Beijing) Biopharmaceuticals Co Ltd(SZSE:300204) pay dividends? If so, how much?
Press Release
Subject | Date | |||
---|---|---|---|---|
No Press Release |